IP Library › Granted Patent US 12,195,518
Granted Patent B2
US 12,195,518 · App. 18/091,361 · Granted Jan 14, 2025

Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof

Inventor: Gray D Shaw (Plymouth, MA)
C07K14/70596A61K38/177A61K39/461A61K39/4631A61K39/464466A61K45/06A61P35/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,518
App. No.
18/091,361
Granted
Jan 14, 2025
Kind
B2
Abstract

Methods of using soluble tandem selectin glycoprotein ligand (TSGL) and TSGL fusion proteins, such as TSGL-Ig, in combination with T cell activation therapies or an adoptive cell transfer (ACT) therapy.

Claims (16)

1. A method of treating a cancer, comprising administering to a subject in need thereof a soluble form of human PSGL-1 in an amount effective to treat the cancer, wherein the soluble form of PSGL-1 comprises a soluble tandem selectin glycoprotein ligand (TSGL) comprising greater than one PSGL-1 domain, wherein each of the greater than one PSGL-1 domains comprises amino acids 5 to 16 of SEQ ID NO:2, and wherein the TSGL molecule is fused to a non-TSGL polypeptide and the TSGL molecule does not contain sialyl Lewis X (sLex) tetrasaccharide.

2. The method of treating a cancer according to claim 1 , wherein the TSGL molecule is fused to a non-TSGL polypeptide; wherein the non-TSGL polypeptide fusion polypeptide is an immunoglobulin Fc and the TSGL molecule does not contain sialyl Lewis X (sLeX) tetrasaccharide.

3. The method of treating a cancer according to claim 1 , wherein the cancer is selected from the group consisting of malignant pleural mesothelioma neuroblastoma or glioblastoma.

4. The method of treating a cancer according to claim 1 , wherein the cancer is selected from the group consisting of multiple myeloma, renal cell and kidney cancer, pancreatic cancer, lung cancer, liver cancer, bile duct cancer, breast cancer, ovarian cancer, testicular and prostate cancer, head and neck cancer, gastrointestinal and stomach cancer, endometrial cancer, bladder cancer, colon, rectal, colorectal, and anal cancer, thyroid cancer, non-melanoma skin cancer, melanoma, lymphoma and leukemia.

5. The method of treating a cancer according to claim 2 , wherein the cancer is selected from the group consisting of malignant pleural mesothelioma neuroblastoma or glioblastoma.

6. The method of treating a cancer according to claim 2 , wherein the cancer is selected from the group consisting of multiple myeloma, renal cell and kidney cancer, pancreatic cancer, lung cancer, liver cancer, bile duct cancer, breast cancer, ovarian cancer, testicular and prostate cancer, head and neck cancer, gastrointestinal and stomach cancer, endometrial cancer, bladder cancer, colon, rectal, colorectal, and anal cancer, thyroid cancer, non-melanoma skin cancer, melanoma, lymphoma and leukemia.

7. The method of claim 1 , further comprising administering at least one other active agent selected from the group consisting of a checkpoint modulator and a protein kinase inhibitor.

8. The method of claim 2 , further comprising administering at least one other active agent selected from the group consisting of a checkpoint modulator and a protein kinase inhibitor.

9. The method of claim 1 , in which one or more threonine (T) residues within the greater than one PSGL-1 domains comprising amino acids 5 to 16 of SEQ ID NO:2 have been replaced by an alanine (A) residue.

10. A method of treating a cancer, comprising administering to a subject in need thereof a soluble form of human PSGL-1 in an amount effective to treat the cancer, wherein the soluble form of PSGL-1 comprises a soluble tandem selectin glycoprotein ligand (TSGL) comprising greater than one PSGL-1 domain, wherein each of the greater than one PSGL-1 domains comprises amino acids 10 to 16 of SEQ ID NO2, and wherein the TSGL molecule is fused to a non-TSGL polypeptide and the TSGL molecule does not contain sialyl Lewis X (sLeX) tetrasaccharide.

11. The method of treating a cancer according to claim 10 , wherein the TSGL molecule is fused to a non-TSGL polypeptide; wherein the non-TSGL polypeptide fusion polypeptide is an immunoglobulin Fc and the TSGL molecule does not contain sialyl Lewis X (sLex) tetrasaccharide.

12. The method of treating a cancer according to claim 10 , wherein the cancer is selected from the group consisting of malignant pleural mesothelioma neuroblastoma or glioblastoma.

13. The method of treating a cancer according to claim 11 , wherein the cancer is selected from the group consisting of multiple myeloma, renal cell and kidney cancer, pancreatic cancer, lung cancer, liver cancer, bile duct cancer, breast cancer, ovarian cancer, testicular and prostate cancer, head and neck cancer, gastrointestinal and stomach cancer, endometrial cancer, bladder cancer, colon, rectal, colorectal, and anal cancer, thyroid cancer, non-melanoma skin cancer, melanoma, lymphoma and leukemia.

14. The method of treating a cancer according to claim 10 , wherein the cancer is selected from the group consisting of malignant pleural mesothelioma neuroblastoma or glioblastoma.

15. The method of treating a cancer according to claim 11 , wherein the cancer is selected from the group consisting of multiple myeloma, renal cell and kidney cancer, pancreatic cancer, lung cancer, liver cancer, bile duct cancer, breast cancer, ovarian cancer, testicular and prostate cancer, head and neck cancer, gastrointestinal and stomach cancer, endometrial cancer, bladder cancer, colon, rectal, colorectal, and anal cancer, thyroid cancer, non-melanoma skin cancer, melanoma, lymphoma and leukemia.

16. The method of claim 10 , in which one or more threonine (T) residues within the greater than one PSGL-1 domains comprising amino acids 10 to 16 of SEQ ID NO:2 have been replaced by an alanine (A).

Continuity (3)
Continuation 16957169
Provisional Application 62611957 · Dec 29, 2017
Related Publication 20230203128A1 · Jun 29, 2023
References Cited (35)
US 8889628B2 · Shaw · 2014 [cited by examiner]
US 9631018B2 · Noelle · 2017 [cited by applicant]
US 9890215B2 · Noelle · 2018 [cited by applicant]
US 10858436B2 · Bradley · 2020 [cited by applicant]
US 20130136741A1 · Shaw · 2013 [cited by applicant]
WO 2018132476 · 2018 [cited by applicant]
WO 201816993 · 2018 [cited by applicant]
WO 2019133454 · 2019 [cited by applicant]
Liang, J-x, et al. (2016) Onco Targets Ther. 9:3113-3125. (doi: 10.2147/OTT.S102389). [cited by examiner]
Zhang C, et al. (Jun. 2017) Am J Transplant. 17(6):1462-1475. (doi: 10.1111/ajt.14159). [cited by examiner]
Matsumoto et al. (2009) Journal of Immunology 183:7204-7211; “P-Selectin Ligand-1 Negatively Regulates T-Cell Immune Responses”. [cited by applicant]
Julien et al. (2007) Journal of Immunology 179:5701-5710; “Sialyl-Lewisx on P-Selectin Ligand-1 is Regulated During Differentiation and Maturation of Dendritic Cells: A Mechanism Involving the Glycotransferases C2GnT1 a… [cited by applicant]
Nolo et al. (2017) Oncotarget 8:86657-86670; “Targeting P-Selectin Blocks Neuroblastoma Growth.” [cited by applicant]
Kawecki et al. (2017) Journal of Thrombosis and Haemostasis 15:1285-1294; “Von Willebrand Factor and Inflammation”. [cited by applicant]
Tsuchihashi et al. (2006) Journal of Immunology 176:616-624; “Molecular Characterization of Rat Leukocyte P-Selectin Glycoprotein Ligand-1 and Effect of Its Blockade: Protection from Ischemia-Reperfusion Injury in Liver… [cited by applicant]
Veerman et al. (2007) Nature Immunology 8:532-539; “Interaction of the Selectin Ligand PSGL-1 with Chemokines CCL21 and CCL19 Facilitates Efficient Homing of T Cells to Secondary Lymphoid Organs”. [cited by applicant]
Teachey et al. (2013) Blood 121:5154-5157) “Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy”. [cited by applicant]
Ferber et al. (2017) eLife 2017:6:e25281 “Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome”. [cited by applicant]
Bonifant et al. (2016) Mol Ther Oncolytics, 3:16011; “Toxicity and management in CAR T-cell therapy”. [cited by applicant]
Gray et al (2022) Front. Immunol.; 13:861670; “Negative Immune Checkpoint Protein, VISTA, Regulates the CD4+ Treg Population During Sepsis Progression to Promote Acute Sepsis Recovery and Survival”. [cited by applicant]
El Tanbouly (2020) Clinical and Experimental Immunology, 200:120-130; “VISTA: Coming of age as a multi-lineage immune checkpoint”. [cited by applicant]
Lines et al. (2014) Cancer Immunol Res; 2:510-517 “VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy”. [cited by applicant]
Hay et al. (2017) Blood 130: 2295-2306; “Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy”. [cited by applicant]
Written Opinion of the International Searching Authority—PCT/US2018/066979 Aug. 16, 2019. [cited by applicant]
Gao et al. (2017) Nature Medicine 23:551-557 “VISTA is an inhibitory immune checkpoint that is increased after pilimumab therapy in patients with prostate cancer”. [cited by applicant]
Deng et al. (2016) J. Immunotherapy of Cancer 4:86 “A New VISTA on combination therapy for negative checkpoint regulator blockade”. [cited by applicant]
Mehta et al. (2020) Nature Scientific Reports 10:15171 “An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA”. [cited by applicant]
Le Mercier et al. (2014) Cancer Research 74:1933-1944 “VISTA Regulates the Development of Protective Antitumor Immunity”. [cited by applicant]
Johnston et al. (2019) Nature 574:565-570 “VISTA is an acidic pH-selective ligand for PSGL-1”. [cited by applicant]
Kappelmayer and Nagy (2017) Biomed Research International 2017:Article ID 6138145 “The Interaction of Selectins and PSGL-1 as a Key Component in Thrombus Formation and Cancer Progression”. [cited by applicant]
Muz et al. (2015) Biomed Research International 2015:Article ID 417586 “Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib”. [cited by applicant]
Melero et al. (2020) J Immunother Cancer 8(supp 3):Abstract 315 “W0180 Novel Anti-VISTA Antibody: Rationale for Target Patient Population and First-in-Human Trial Design in Monotherapy and in Combination with Anti-PD1 A… [cited by applicant]
Lines et al. (2020) J Immunother Cancer 8(supp 3):Abstract 447 “VISTA Targeting Remodels the Tumor Microenvironment to Overcome Adaptive Resistance”. [cited by applicant]
Natoni et al. (2016) Frontiers in Oncology, 6:93 “Targeting Selectins and Their Ligands in Cancer.” [cited by applicant]
Azab et al. (2012) Blood. 2012;119(6):1468-1478. [cited by applicant]